Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 2501 - 2600
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 2501 | 26684863 |
US |
50 | 1 |
Dermatitis atopic, Pruritus, Inflammation, Spondylitis, Asthma, Dyspnoea, Chest discomfort, Intentional product use issue, |
||||
DUPILUMAB, |
||||
| 2502 | 26684992 |
EU |
36 | 1 |
Seizure, Swelling of eyelid, Steroid dependence, Skin exfoliation, Product use in unapproved indication, Peripheral swelling, Swelling, Burning sensation, Drug ineffective, Inflammatory pain, Arthritis, Scab, Joint swelling, Inflammation, Pain in extremity, Pruritus, Wound secretion, Product prescribing error, Sleep disorder, Erythema, Withdrawal syndrome, Eyelid margin crusting, Therapy cessation, Off label use, Topical steroid withdrawal reaction, Movement disorder, Dermatitis atopic, Asthenia, Skin swelling, |
||||
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, BETAMETHASONE DIPROPIONATE, DESONIDE, DESONIDE, DESONIDE, DESONIDE, DESONIDE, BETAMETHASONE VALERATE, BETAMETHASONE VALERATE FOAM, BETAMETHASONE VALERATE, BETAMETHASONE VALERATE FOAM, |
||||
| 2503 | 26685311 |
US |
62 | 1 |
Dermatitis atopic, Rash, Product dose omission issue, Discomfort, |
||||
DUPILUMAB, AMLODIPINE, ABROCITINIB, CLONIDINE, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, |
||||
| 2504 | 26685720 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2505 | 26685846 |
US |
2 | |
Dermatitis atopic, Rash, Discomfort, |
||||
DUPILUMAB, DESONIDE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, |
||||
| 2506 | 26685860 |
US |
15 | 2 |
Dermatitis atopic, Dry skin, Skin exfoliation, Off label use, |
||||
DUPILUMAB, |
||||
| 2507 | 26685868 |
US |
2 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 2508 | 26685920 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, HYDROXYZINE, MONTELUKAST SODIUM, MONTELUKAST, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, CETIRIZINE HYDROCHLORIDE, |
||||
| 2509 | 26685928 |
US |
38 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2510 | 26685940 |
US |
49 | 2 |
Eczema, Dry skin, Skin exfoliation, Dermatitis contact, Dermatitis atopic, Rash macular, Rash macular, Skin discolouration, Rash macular, |
||||
DUPILUMAB, DUPILUMAB, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, |
||||
| 2511 | 26685955 |
US |
1 | |
Dermatitis atopic, Drug ineffective, Product dose omission in error, |
||||
DUPILUMAB, BACLOFEN, DULOXETINE HYDROCHLORIDE, PREGABALIN, |
||||
| 2512 | 26686229 |
US |
13 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2513 | 26686491 |
US |
70 | 2 |
Dermatitis atopic, Rash, Sleep disorder due to a general medical condition, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2514 | 26686818 |
US |
28 | 2 |
Feeling hot, Stress, Fatigue, Insomnia, Injection site urticaria, Injection site bruising, Dermatitis atopic, Urticaria, |
||||
DUPILUMAB, |
||||
| 2515 | 26686819 |
US |
11 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2516 | 26686820 |
US |
22 | 2 |
Dermatitis atopic, Scratch, |
||||
DUPILUMAB, |
||||
| 2517 | 26686828 |
US |
75 | 2 |
Dermatitis atopic, Pruritus, Rash, Dry skin, Drug ineffective, Skin discolouration, |
||||
DUPILUMAB, |
||||
| 2518 | 26686833 |
US |
49 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2519 | 26686915 |
US |
52 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2520 | 26686916 |
US |
15 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2521 | 26686959 |
US |
64 | 1 |
Dermatitis atopic, Rash erythematous, Pruritus, Skin burning sensation, Dermatitis, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2522 | 26687000 |
US |
43 | 1 |
Nasopharyngitis, Dermatitis atopic, Pruritus, Therapeutic response shortened, Product storage issue, Device issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2523 | 26687004 |
US |
21 | 2 |
Dermatitis atopic, Skin exfoliation, Erythema, Treatment noncompliance, |
||||
DUPILUMAB, LEVONORGESTREL, |
||||
| 2524 | 26687008 |
US |
60 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2525 | 26687026 |
US |
1 | |
Dermatitis atopic, |
||||
LEBRIKIZUMAB-LBKZ, |
||||
| 2526 | 26687028 |
US |
31 | 2 |
Dermatitis atopic, Eyelid skin dryness, |
||||
DUPILUMAB, |
||||
| 2527 | 26687029 |
US |
41 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2528 | 26687041 |
US |
51 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2529 | 26687054 |
US |
13 | 1 |
Rash erythematous, Scratch, Pruritus, Skin burning sensation, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2530 | 26687141 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2531 | 26687143 |
US |
72 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2532 | 26687144 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2533 | 26687148 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2534 | 26687168 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2535 | 26687169 |
US |
27 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2536 | 26687183 |
US |
23 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2537 | 26687208 |
US |
45 | 2 |
Injection site warmth, Injection site erythema, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2538 | 26687209 |
US |
6 | 1 |
Dermatitis atopic, Skin irritation, Eczema, |
||||
DUPILUMAB, |
||||
| 2539 | 26687210 |
US |
27 | 2 |
Dermatitis atopic, Fatigue, Drug ineffective, Pruritus, Sleep disorder due to a general medical condition, Dry skin, |
||||
DUPILUMAB, |
||||
| 2540 | 26687511 |
CO |
19 | 2 |
Circulatory collapse, Syncope, Hypersensitivity, Angioedema, Vomiting, Pain of skin, Flushing, Urticaria, Diarrhoea, Tachycardia, Nausea, Erythema, Skin burning sensation, Abdominal pain, Hypotension, Pruritus, Rash pruritic, Malaise, Gastrointestinal pain, Myalgia, Dermatitis atopic, Arthralgia, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 2541 | 26678436 |
US |
76 | 2 |
Dermatitis atopic, |
||||
DELGOCITINIB, |
||||
| 2542 | 26678865 |
US |
32 | 2 |
Dermatitis atopic, Eczema, |
||||
DUPILUMAB, |
||||
| 2543 | 26678877 |
US |
64 | 1 |
Pruritus, Sleep disorder, Skin haemorrhage, Skin weeping, Skin fissures, Dry skin, Skin exfoliation, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 2544 | 26678904 |
US |
23 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, ABROCITINIB, |
||||
| 2545 | 26678907 |
US |
84 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2546 | 26678910 |
US |
65 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2547 | 26678928 |
US |
5 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2548 | 26678929 |
US |
51 | 2 |
Dermatitis atopic, Skin fissures, |
||||
DUPILUMAB, |
||||
| 2549 | 26678945 |
US |
11 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2550 | 26678972 |
US |
57 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2551 | 26678986 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2552 | 26678992 |
US |
27 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2553 | 26679000 |
US |
11 | 2 |
Pruritus, Dermatitis atopic, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2554 | 26679016 |
US |
26 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2555 | 26679020 |
US |
29 | 1 |
Injection site pain, Dermatitis atopic, Drug effect less than expected, Rash, Skin exfoliation, |
||||
DUPILUMAB, |
||||
| 2556 | 26679023 |
US |
1 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2557 | 26679084 |
US |
22 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 2558 | 26679088 |
US |
73 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2559 | 26679091 |
US |
22 | 2 |
Stress, Multiple allergies, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2560 | 26679093 |
US |
22 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2561 | 26679096 |
US |
24 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2562 | 26679187 |
US |
42 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 2563 | 26679190 |
US |
82 | 2 |
Dermatitis atopic, Contusion, Pruritus, Erythema, |
||||
DUPILUMAB, NEMOLIZUMAB-ILTO, |
||||
| 2564 | 26679192 |
US |
42 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2565 | 26679198 |
US |
78 | 2 |
Dermatitis atopic, Pruritus, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 2566 | 26679212 |
US |
2 | |
Skin exfoliation, Erythema, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2567 | 26679220 |
US |
12 | 2 |
Dermatitis atopic, Staphylococcal infection, |
||||
DUPILUMAB, |
||||
| 2568 | 26679231 |
US |
5 | 2 |
Eczema, Pruritus, Dermatitis atopic, Weight increased, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2569 | 26679238 |
US |
13 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2570 | 26679247 |
US |
65 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2571 | 26679248 |
US |
45 | 2 |
Urticaria, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2572 | 26679252 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2573 | 26679257 |
US |
66 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2574 | 26679276 |
US |
70 | 2 |
Joint swelling, Arthralgia, Dermatitis atopic, Skin swelling, |
||||
DUPILUMAB, ADALIMUMAB, NEMOLIZUMAB-ILTO, |
||||
| 2575 | 26679300 |
US |
63 | 2 |
Dermatitis atopic, Rash, Pruritus, Eye irritation, Pain in extremity, Fatigue, Product use in unapproved indication, Drug ineffective, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2576 | 26679357 |
US |
1 | |
Discomfort, Sleep disorder due to a general medical condition, Rash, Dermatitis atopic, |
||||
DUPILUMAB, BETAMETHASONE DIPROPIONATE, CRISABOROLE, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, LISDEXAMFETAMINE DIMESYLATE, |
||||
| 2577 | 26679358 |
US |
21 | 2 |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 2578 | 26679405 |
US |
13 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2579 | 26679409 |
US |
43 | 1 |
Dermatitis atopic, Rash erythematous, Pruritus, Skin burning sensation, |
||||
DUPILUMAB, |
||||
| 2580 | 26679422 |
US |
23 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2581 | 26679446 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 2582 | 26679458 |
US |
||
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 2583 | 26679493 |
US |
16 | 2 |
Dermatitis atopic, Rash, Discomfort, |
||||
DUPILUMAB, |
||||
| 2584 | 26679501 |
US |
2 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, CYANOCOBALAMIN, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, TIRZEPATIDE, CETIRIZINE HYDROCHLORIDE, |
||||
| 2585 | 26679509 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2586 | 26679515 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 2587 | 26679516 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2588 | 26679517 |
US |
2 | |
Injection site pain, Therapeutic response shortened, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, ALBUTEROL SULFATE, BUPROPION, CETIRIZINE HCL, CETIRIZINE, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE, FLUOCINONIDE, FLUOCINONIDE TOPICAL SOLUTION USP, 0.05%, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, MAGNESIUM, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, MONTELUKAST SODIUM, MONTELUKAST, PANTOPRAZOLE SODIUM, |
||||
| 2589 | 26680908 |
US |
||
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 2590 | 26681564 |
US |
65 | |
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 2591 | 26673164 |
US |
64 | 1 |
Dry skin, Skin exfoliation, Dermatitis atopic, |
||||
ORAL SEMAGLUTIDE, |
||||
| 2592 | 26673810 |
US |
59 | 1 |
Dry skin, Dermatitis atopic, Condition aggravated, Pruritus, Condition aggravated, Weight decreased, |
||||
ORAL SEMAGLUTIDE, DUPILUMAB, |
||||
| 2593 | 26671742 |
US |
||
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 2594 | 26671824 |
US |
47 | 2 |
Dermatitis atopic, Rash erythematous, Pruritus, Skin burning sensation, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 2595 | 26671862 |
US |
2 | |
Dermatitis atopic, Eye irritation, Vision blurred, |
||||
DUPILUMAB, |
||||
| 2596 | 26671863 |
US |
10 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2597 | 26671869 |
US |
1 | 1 |
Rash papular, Dermatitis atopic, |
||||
DUPILUMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, |
||||
| 2598 | 26666660 |
GB |
||
Peripheral swelling, Eczema, Pruritus, Erythema, Peripheral coldness, Sticky skin, Purulent discharge, Decreased appetite, Dermatitis atopic, Bacterial infection, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 2599 | 26667066 |
US |
59 | 2 |
Renal cancer, Dermatitis atopic, Skin burning sensation, Pruritus, Rash, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 2600 | 26667314 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30